Research programme: KRAS G12V targeting T cell therapies - Affini-T Therapeutics
Latest Information Update: 23 Jun 2022
At a glance
- Originator Affini-T Therapeutics
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer